

103. Miller IM, Vinding G, Zarchi K, Esmann S, Murrell DF, Jemec GB. Differences in disease-specific quality of life in patients with actinic keratosis in Australia and Denmark. *Acta Dermatovenerol Croat*. 2016;24:25-28.
104. Lee K, Weinstock M. Prospective quality of life impact of actinic keratoses: observations from the veterans affairs topical tretinoin chemoprevention trial. *Acta Derm Venereol*. 2011;91:101-102.
105. Vis K, Waalboer-Spuij R, Snels DGCT, Hollestein LM. Validity and reliability of the Dutch adaptation of the Actinic Keratosis Quality of Life Questionnaire (AKQoL). *Dermatology*. 2018;234:60-65.
106. Philipp-Dormston WG, Müller K, Novak B, et al. Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a large-scale observational study analysing effects of diagnoses and disease progression. *J Eur Acad Dermatol Venereol*. 2018;32:1138-1146.
107. Longo I, Serra-Guillén C. Quality of life, behaviour and attitudes towards actinic keratosis in Spain: the PIQA Study. *Actas Dermosifiliogr*. 2018;109:331-339.

---

## Answers to CME examination

Identification No. JA0920

September 2020 issue of the Journal of the American Academy of Dermatology.

Willenbrink TJ, Ruiz ES, Cornejo CM, Schmults CD, Arron S, Jambusaria-Pahlajani A. *J Am Acad Dermatol* 2020;83:709-17.

1. b  
2. b

3. c